Improving survival among those with advanced cancer along with a high rate of cancer-related pain in this patient population will lead to steady growth in the prevalence of cancer pain in the seven…
Improving survival among those with advanced cancer along with a high rate of cancer-related pain in this patient population will lead to steady growth in the prevalence of cancer pain in the seven…
Improving survival among those with advanced cancer along with a high rate of cancer-related pain in this patient population will lead to steady growth in the prevalence of cancer pain in the…
Last Updated 29 October 2015 The treatment of breast cancer has a rich and diverse product pipeline and continues to be one of the most lucrative and active areas of research in oncology. However,…
Is There a Disconnect Between Physician and Payer Perceptions of Therapies Across Key Indications? The treatment of both solid and hematological cancers is associated with a wide range of serious…
Last Updated 23 October 2015 Biomarker- and histology-driven prescribing has become standard practice in the treatment of non-small-cell lung cancer (NSCLC). The treatment algorithms for NSCLC—…
Last Updated 22 October 2015 The drug treatment of prostate cancer has evolved rapidly over the last few years—the metastatic castrate-resistant prostate cancer (mCRPC) setting has become crowded…
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant public health and financial burden. The expansion of the treatment labels…
LaunchTrends: Ibrance (Wave 2) is the second in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched breast cancer…
Over the next ten years, more than 15 million men worldwide will be diagnosed with prostate cancer, resulting in nearly 3 million first-line drug-treatment opportunities in the metastatic castrate-…
How Will Physician and Payer Attitudes and Decisions Shape this Market? The treatment of metastatic colorectal cancer (mCRC) is increasingly driven by patients’ RAS mutational status of their…
The late-stage development pipeline for non-small-cell lung cancer (NSCLC) is one of the busiest pipelines in oncology, with approximately 25 novel therapies in Phase III development. Several of…
Cancer treatment is rapidly evolving and demand for more than modest incremental efficacy gains in highly competitive markets is growing. Given the complexity of the multiple pathways and aberrant…
Gastric and gastroesophageal junction (GEJ) adenocarcinoma is characterized by poor prognosis. Japan has the highest incidence of gastric and GEJ adenocarcinoma among the markets under study,…
The ovarian cancer therapy market retains its potential for commercial reward for drug developers. Although the disease tends to respond well initially to chemotherapy and current drug treatment…